2018 Exocrine Pancreatic Insufficiency Drug Development- Pipeline Analysis Report
Absence of adequate digestive enzymes in a patient results in occurrence of Exocrine Pancreatic Insufficiency (EPI). Pancreas fail to produce the required enzymes to digest food and nutrient absorption. The market is valued at around $1.2 billion.
Over 10 companies and universities are focusing on developing treatment options for Exocrine Pancreatic Insufficiency.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Exocrine Pancreatic Insufficiency pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Exocrine Pancreatic Insufficiency pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Exocrine Pancreatic Insufficiency pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Over 10 companies and universities are focusing on developing treatment options for Exocrine Pancreatic Insufficiency.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Exocrine Pancreatic Insufficiency pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Exocrine Pancreatic Insufficiency pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Exocrine Pancreatic Insufficiency pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of Figures
1.2 List of Tables
2 EXOCRINE PANCREATIC INSUFFICIENCY PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Exocrine Pancreatic Insufficiency Pipeline Snapshot
2.3 Exocrine Pancreatic Insufficiency Pipeline by Phase
2.4 Exocrine Pancreatic Insufficiency Pipeline by Company
2.5 Exocrine Pancreatic Insufficiency Pipeline by Mechanism of Action
3 EXOCRINE PANCREATIC INSUFFICIENCY - COMPANY WISE PIPELINE ANALYSIS
Anthera Pharmaceuticals Inc
AstraZeneca Plc
Cilian AG
Laboratoires Mayoly Spindler SAS
Nordmark Arzneimittel GmbH & Co KG
4 EXOCRINE PANCREATIC INSUFFICIENCY R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN EXOCRINE PANCREATIC INSUFFICIENCY PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of Figures
1.2 List of Tables
2 EXOCRINE PANCREATIC INSUFFICIENCY PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Exocrine Pancreatic Insufficiency Pipeline Snapshot
2.3 Exocrine Pancreatic Insufficiency Pipeline by Phase
2.4 Exocrine Pancreatic Insufficiency Pipeline by Company
2.5 Exocrine Pancreatic Insufficiency Pipeline by Mechanism of Action
3 EXOCRINE PANCREATIC INSUFFICIENCY - COMPANY WISE PIPELINE ANALYSIS
Anthera Pharmaceuticals Inc
AstraZeneca Plc
Cilian AG
Laboratoires Mayoly Spindler SAS
Nordmark Arzneimittel GmbH & Co KG
4 EXOCRINE PANCREATIC INSUFFICIENCY R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN EXOCRINE PANCREATIC INSUFFICIENCY PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Exocrine Pancreatic Insufficiency Pipeline by Phase, H1- 2018
Figure 2: Exocrine Pancreatic Insufficiency Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Exocrine Pancreatic Insufficiency Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
Figure 1: Exocrine Pancreatic Insufficiency Pipeline by Phase, H1- 2018
Figure 2: Exocrine Pancreatic Insufficiency Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Exocrine Pancreatic Insufficiency Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Exocrine Pancreatic Insufficiency Pipeline by Phase, H1- 2018
Table 2: Exocrine Pancreatic Insufficiency Pipeline by Companies, H1- 2018
Table 3: Exocrine Pancreatic Insufficiency Pipeline by Mechanism of Action, H1- 2018
Table 4: Anthera Pharmaceuticals Inc Exocrine Pancreatic Insufficiency pipeline, May 2018
Table 5: AstraZeneca Plc Exocrine Pancreatic Insufficiency pipeline, May 2018
Table 6: Cilian AG Exocrine Pancreatic Insufficiency pipeline, May 2018
Table 7: Laboratoires Mayoly Spindler SAS Exocrine Pancreatic Insufficiency pipeline, May 2018
Table 8: Nordmark Arzneimittel GmbH & Co KG Exocrine Pancreatic Insufficiency pipeline, May 2018
Table 1: Exocrine Pancreatic Insufficiency Pipeline by Phase, H1- 2018
Table 2: Exocrine Pancreatic Insufficiency Pipeline by Companies, H1- 2018
Table 3: Exocrine Pancreatic Insufficiency Pipeline by Mechanism of Action, H1- 2018
Table 4: Anthera Pharmaceuticals Inc Exocrine Pancreatic Insufficiency pipeline, May 2018
Table 5: AstraZeneca Plc Exocrine Pancreatic Insufficiency pipeline, May 2018
Table 6: Cilian AG Exocrine Pancreatic Insufficiency pipeline, May 2018
Table 7: Laboratoires Mayoly Spindler SAS Exocrine Pancreatic Insufficiency pipeline, May 2018
Table 8: Nordmark Arzneimittel GmbH & Co KG Exocrine Pancreatic Insufficiency pipeline, May 2018
